CCMH
TVRD

Cornerstone Capital Management Holdings’s Tvardi Therapeutics TVRD Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-428
Closed -$96K – 1507
2016
Q1 		$96K Buy
428
+197
+85% +$58.8K ﹤0.01% 1318
2015
Q4 		$140K Buy
231
+123
+114% +$67.5K ﹤0.01% 1271
2015
Q3 		$55K Buy
+108
New +$72.3K ﹤0.01% 1395

Other funds holding TVRD

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cornerstone Capital Management Holdings's TVRD Position: Q2 2016 in Review

Cornerstone Capital Management Holdings sold out of Tvardi Therapeutics (TVRD) in Q2 2016, closing a stake of 428 shares — an estimated $96K sold.

Cornerstone Capital Management Holdings first reported a position in TVRD in Q3 2015 and held it in 3 quarters. The position peaked at $140K in Q4 2015. 70 funds tracked by Wall St. Rank hold TVRD as of Q2 2016.

  • Cornerstone Capital Management Holdings reported no remaining Tvardi Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Cornerstone Capital Management Holdings sold 428 Tvardi Therapeutics shares in Q2 2016, an estimated $96K.
  • Cornerstone Capital Management Holdings first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 3 quarters.
  • Cornerstone Capital Management Holdings's Tvardi Therapeutics position peaked at $140K in Q4 2015.
  • 70 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.